Millennium Management LLC reduced its position in shares in Halozyme Therapeutics, Inc. (NASDAQ: HALO) by 94.0% in the second quarter, according to the company in its latest release with the SEC. The company owned 82,714 shares in the biopharmaceutical company's share after sale of 1,290,533 shares during the quarter. Millennium Management LLC owned approximately 0.06% of Halozyme Therapeutics worth $ 1,395,000 at the end of the last reporting period.
Several other hedge funds and other institutional investors have also recently made changes in their positions in the company. Raymond James & Associates acquired a new position in Halozyme Therapeutics shares in the second quarter, valued at approximately $ 222,000. Amalgamated Bank increased its holding in Halozyme Therapeutics shares by 19.3% in the second quarter. Amalgamated Bank now owns 19,053 shares in the biopharmaceutical company's share valued at 321,000 USD after acquiring 3 077 shares in the last quarter. Xact Kapitalforvaltning AB increased its holding in Halozyme Therapeutics by 26.1% during the 1st quarter. Xact Kapitalforvaltning AB now owns 18,369 shares in the biopharmaceutical company's share worth $ 360,000 after acquisition of additional 3,800 shares during the last quarter. Cubistic Systematic Strategies LLC increased their holding in Halozyme Therapeutics by 69.1% in the second quarter. Cubist Systematic Strategies LLC now owns 22,346 shares in the biopharmaceutical company's share worth $ 377,000 after acquisition of another 9,134 shares during the last quarter. Finally, CIBC Private Wealth Group LLC grew its holding in Halozyme Therapeutics by 15.9% in the second quarter. CIBC Private Wealth Group LLC now owns 25,776 shares in the biopharmaceutical company's share worth $ 435,000 after acquisition of another 3,541 shares during the last quarter. Institutional investors and hedge funds own 84.68% of the company's share.
Several research analysts have commented on HALO shares. Cantor Fitzgerald set a $ 27.00 prize on shares in Halozyme Therapeutics and gave the stock company a "buy" rating in a report on Thursday, October 25th. Piper Jaffray Companies repeated a "neutral" rating of shares of Halozyme Therapeutics in a report on Friday, October 19th. BidaskClub upgraded shares of Halozyme Therapeutics from a "team" rating to a "buy" rating in a report Wednesday 3 October. ValuEngine upgraded shares in Halozyme Therapeutics from a "team" rating to a "buy" rating in a research report Wednesday 3 October. Finally, BMO Capital Markets' price target for Halozyme Therapeutics's shares increased from $ 19.00 to $ 21.00, giving the stock company a rating on the market in a research report on Wednesday, August 8. A research analyst has rated the share with a sales rating, five have issued a rating and five have assigned a purchase price to the share. The company has an average rating of "Team" and a consensus goal of $ 20.56.
In related news, the main shareholder Randal J. Kirk sold 1,194,462 shares of shares in a transaction dated 23rd of August. The shares were sold at an average price of $ 17.65, for a total value of $ 21,082,254.30. Following the sale, the holder now owns 3,562,388 shares of the company, valued at approximately 62,876,148.20 dollars. The sale was disclosed in a filing with SEC, available through this hyperlink. Major shareholders Randal J. Kirk also sold 644,998 shares of shares in a transaction dated 28 August. The shares were sold at an average of 18.08 USD, for a total transaction of 11 661 563.84 USD. After completion of sales, the company now owns directly 3,562,388 shares in the company valued at 64,407,975.04 USD. The information for this sale can be found here. Over the last ninety days, insiders have sold 2,000,706 shares of corporate shares worth $ 35,509,187. Corporate inspectors own 14.10% of the company's share.
HALO stocks opened at $ 16.20 on Friday. Halozyme Therapeutics, Inc. has a 12 month low of $ 14.33 and a 12 month high of $ 21.48. The company has a market value of $ 2.18 billion, a P / E ratio of 35.90 and a beta of 1.88. The company has a fast ratio of 2.96, a present value of 3.09 and a debt ratio of 0.24.
Halozyme Therapeutics (NASDAQ: HALO) announced last quarterly results data Tuesday, November 6th. The biopharmaceutical company reported ($ 0.19) EPS for the quarter, which peaked Zack's consensus estimate of ($ 0.23) by $ 0.04. The company had a turnover of $ 25.60 million during the quarter compared with the $ 30.42 million consensus estimate. Halozyme Therapeutics had a net margin of 16.24% and a return on equity of 18.87%. Halozyme Therapeutics quarterly revenue decreased by 59.8% compared with the previous year. In the same quarter last year, the company earned $ 0.02 EPS. On average, analysis analysts forecast that Halozyme Therapeutics, Inc. will receive -0.59 earnings per share for the current fiscal year.
TRADE MESSAGE USER INFORMATION: This news story was first reported by Fairfield Current and is the property of Fairfield Current. If you access this news article in another publication, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The legal version of this news article can be read at https://www.fairfieldcurrent.com/2018/11/16/millennium-management-llc-cuts-stake-in-halozyme-therapeutics-inc-halo.html.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops and commercializes human enzymes and other drug candidates in the United States, Switzerland and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, which improves the effectiveness and convenience of other drugs or can be used to change tissue structures for clinical benefit.
See also: Penny Stocks, Risk and Reward Factors
Receive news and ratings for Halozyme Therapeutics Daily – Enter your email address below to get a brief daily summary of the latest news and analysts reviews for Halozyme Therapeutics and related companies with MarketBeat.com's FREE Daily Newsletter.